| Document |
Document Title |
|
WO/2022/166774A1 |
The present invention provides a crystal of a compound represented by formula I as a 3-hydroxy-5-pregnane-20-one derivative and a preparation method therefor. Specifically, the present invention provides novel crystal forms A-C of the co...
|
|
WO/2022/150637A1 |
The invention provides novel glucocorticosteroids, glucocorticosteroid-linkers and antibody drug conjugates (ADC's) comprising an antibody or antibody fragment which binds to an antigen expressed on immune cells, optionally an antigen ex...
|
|
WO/2022/115381A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a p...
|
|
WO/2022/084752A1 |
The present invention relates to a process for the preparation of 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-ene-3,20-dione (VI) having the formula below: Compound (VI) can be used as a precursor for the synthesis of Clascoterone, a steroi...
|
|
WO/2022/053937A1 |
The present invention refers to a process for preparing (3α,5α)-3 -hydroxy-3 -methyl- pregnan-20-one, a compound also known as Ganaxolone, having the formula below: (I).
|
|
WO/2022/034582A1 |
Described herein are novel, macrophage targeting drug conjugates. The macrophage targeting drug conjugates comprise a drug moiety, a mannose moiety, and a linker connecting the drug moiety and the mannose moiety. The linker may comprise ...
|
|
WO/2022/016150A1 |
The present disclosure describes methods for treating cytokine release syndromes, and more particularly to methods using soft corticosteroids to treat the effects of said syndromes in the lungs.
|
|
WO/2021/262836A1 |
Provided herein is a compound of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16,R17, R19, RX, RY, and t are defined herein. Also provided herein are...
|
|
WO/2021/238312A1 |
Disclosed is a method for purifying progesterone, belonging to the technical field of preparation and processing of steroid hormone medicaments. In the method, aldehyde impurities in crude progesterone are used to react with a sulfur-con...
|
|
WO/2021/184502A1 |
Disclosed in the present invention is a method for preparing 16alpha-hydroxyprednisolone, belonging to the technical field of medicine preparation and processing. In the method, 21-hydroxypregna-1,4,9(11),16-tetraene-3,20-dione-21-acetat...
|
|
WO/2021/167770A1 |
Disclosed are immune cell-selective small molecule compounds that modulate certain immune cell-specific receptors and enzymes, and methods of their synthesis and use to treat proliferative disorders.
|
|
WO/2021/142145A1 |
A compound of the formula (I): G1-L-G2, or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein G1 is a folate radical, an antifolate radical, or a folate analog radical; L is a linker; and G2 is ...
|
|
WO/2021/113068A1 |
The invention provides novel neuroactive steroids and pharmaceutical compositions thereof, as well as methods of their preparation and use, in therapy of various diseases and conditions, for example, various neurological or brain diseases.
|
|
WO/2021/098872A1 |
The present invention relates to a compound represented by general formula (I) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, and the pharmaceutical use thereof. The compound of general formula (I) has a str...
|
|
WO/2021/093494A1 |
Disclosed is a production process capable of industrially synthesizing dydrogesterone. The dydrogesterone is prepared by using a readily available progesterone as a raw material through the steps of carbonyl protection, bromination, debr...
|
|
WO/2021/027744A1 |
Provided in the present invention are a 3-hydroxy-5-pregnane-20-one derivative as shown in formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the derivative or the pharmaceutically accept...
|
|
WO/2021/023213A1 |
The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effect...
|
|
WO/2021/012671A1 |
Disclosed is a highly efficient preparation method for progesterone with low pollution, pertaining to the technical field of preparation and processing of steroid hormone drugs. The method uses 21-hydroxy-20-methylpregna-4-en-3-one as a ...
|
|
WO/2020/264512A1 |
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...
|
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
|
WO/2020/245641A1 |
The present disclosure relates to novel ester forms of medroxyprogesterone, process for their preparation and pharmaceutical compositions comprising the same. The present disclosure also relates to use of the novel ester forms in hormona...
|
|
WO/2020/243488A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...
|
|
WO/2020/210116A1 |
The invention provides steroid compounds with altered pharmacological properties and methods of using the compounds to treat a condition in a subject.
|
|
WO/2020/187965A1 |
The invention relates to an efficient and industrially applicable process for the preparation and purification of allopregnanolone and intermediates thereof without the assistance of column chromatography.
|
|
WO/2020/185710A1 |
The present disclosure relates to methods of alleviating a symptom of, treating, or preventing a sleep disorder by administering a neurosteroid GABAA positive allosteric modulator or pharmaceutically acceptable salt thereof to a subject ...
|
|
WO/2020/181395A1 |
The present application relates to a rinse-off composition comprising an oil phase and an aqueous surfactant matrix, wherein one or more active agents are dissolved in one or more non-polar, water-immiscible solvents, and the oil phase i...
|
|
WO/2020/135352A1 |
Disclosed is a method for preparing a progesterone particulate, especially a crystal or powder. The method comprises: step 1, dissolving progesterone in a solvent to provide a progesterone solution; step 2, pumping the progesterone solut...
|
|
WO/2020/132504A1 |
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...
|
|
WO/2020/124094A1 |
The invention relates to methods of treating depression with Compound 1 or pharmaceutically acceptable salts thereof. The present disclosure, among other things, provides methods of treating depression by administering a therapeutically ...
|
|
WO/2020/118142A1 |
Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and...
|
|
WO/2020/083839A1 |
The present invention relates to a new process for the synthesis of 3a-hydroxy-5a-pregnan-20-one, commonly known as brexanolone, wherein the corresponding cyclic 20-ketal or cyclic 20-thioketal compound of formula (IV) is deprotected wit...
|
|
WO/2020/082065A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3, R6a, R6b, R2a, R2b, R4a, R4b, R7a, R7b, R11, R12a, R12b, R16, R21a, R21b, and R21c are defined herein. Also provided here...
|
|
WO/2020/077255A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. ...
|
|
WO/2020/006596A1 |
Disclosed are neuroactive steroid anaesthetic agents, methods for their preparation and compositions comprising the same. The invention provides scaled up and/or GMP methods for preparing neuroactive steroids, such as alfaxalone, alfadol...
|
|
WO/2020/000080A1 |
A system for preventing and treating the bends and blockages of blood flow, such as heart attacks and ischemic strokes. The system comprises the application of ultrasound, with cooling of the affected body area, to break up and reduce in...
|
|
WO/2019/211668A2 |
The present invention contemplates novel neurosteroid derivative compounds, such as derivatives of ganaxolone and allopregnanolone, having improved solubility and bioavailability. The novel neurosteroid derivative compounds are character...
|
|
WO/2019/154257A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...
|
|
WO/2019/154247A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound as shown in formula (I), a preparation method therefor, a pharma...
|
|
WO/2019/128154A1 |
Provided is a method for synthesizing the 17-position side chain of a steroid drug, wherein same is characterized in using compound I as a starting material, and the 17-position side chain is synthesized by nucleophilic, esterification, ...
|
|
WO/2019/126741A1 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
WO/2019/113494A1 |
Provided herein is a deuterated compound of Formula (I) Formula (I) or a pharmaceutically acceptable salt thereof, wherein R3a,R5, R6a, R6b, R17, R21a, R21b, Rm, Rn, R16a, R16 b, R7a, R7b, R12a, R12b, R11a R11b, R2a, R2b, R19, R4a, and R...
|
|
WO/2018/222701A1 |
The present application relates to methods of treating or preventing a renal disease, disorder, or condition (e.g., age-, diabetes- and/or obesity-related renal disease, disorder, or condition) in a subject in need thereof, comprising ad...
|
|
WO/2018/137260A1 |
Disclosed in the present application is a method for preparing a compound I, which is characterized in being prepared and obtained by reacting starting materials which comprise a compound II, which contains a carbon-carbon double bond, a...
|
|
WO/2018/127601A1 |
The present invention relates to aseptic suspensions, physically stable and injectable through a 25G needle or thinner, comprising crystalline, non- micronized 3-beta-hydroxy-5-alpha-pregnan-20-one particles, a mixture of acylglycerols a...
|
|
WO/2018/109508A1 |
The invention relates to the last step of a synthetic process, in which Nomegestrol- acetate of formula (I) is synthesized from 17α-acetoxy-6-methylene-19-norpregn-4-ene-3,20-dione of formula (II) in the presence of Pd/C catalyst and ac...
|
|
WO/2018/103626A1 |
The present invention relates to the field of medicine, and particularly relates to a water-soluble allopregnenolone derivative, a pharmaceutical composition comprising the same, and use thereof in prevention or treatment of central nerv...
|
|
WO/2018/064649A1 |
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention ...
|
|
WO/2018/013615A1 |
Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b,R12, R16, R17, R19, and ----- are as define...
|
|
WO/2018/013613A1 |
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...
|
|
WO/2017/150723A1 |
Algae that generates a sterol and a sterol production method that uses the algae. According to the present invention, a sterol is produced by culturing algae, such as strain AJ7867 (FERM BP-22304) and strains derived therefrom, that has ...
|
